Insufficient Evidence Regarding Osteoporosis Medications in Kidney Patients

“More research is needed, particularly among patients with chronic kidney disease stages 3 to 5, to determine the safety and effectiveness of osteoporosis medications in patients with CKD,” Dr. Robinson concludes.

“Studies should be adequately powered to show a reduction in the risk for fractures and should have sufficient follow-up (>=3 years),” the researchers note. “Future research should also provide details about trial methods, should specify a priori how outcomes will be measured and reported, and should report on adverse events and safety.”

Reference

1. Wilson LM, Rebholz CM, Jirru E, et al. Benefits and harms of osteoporosis medications in patients with chronic kidney disease: A systematic review and meta-analysis. Ann Intern Med. 2017 Apr 11. doi: 10.7326/M16-2752. [Epub ahead of print]